An observational study in Sars-CoV-2 Infection, sponsored by Pontificia Universidad Catolica de Chile. Status unknown at 1 site in Chile. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-02.
Sponsored by Pontificia Universidad Catolica de Chile · Observational
The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and rapidly approved. Novel mRNA vaccines such as the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have reported a stunning >94% efficacy against COVID-19. However, global access has not been equitable, with many low- and middle-income countries having no vaccine access or access under emergency use mainly to traditional inactivated SARS-CoV2-2 vaccines such as BBIBP-CorV (Sinopharm Beijing), CoronaVac (Sinovac) and BBV152 (Bharat Biotech). Emerging studies have shown that lower concentrations of neutralizing antibodies (Nab) are attained after CoronaVac than after a mRNA-based vaccine in healthy individuals. This difference seems to be more pronounced in immunocompromised patients who are at higher risk of severe COVID-19 and death from COVID-19. As such several countries including United States, Israel and Chile have recommended a third vaccine dose for this vulnerable population.
In this observational study we will explore the humoral response to the BNT162b2 vaccine in patients who received two previous doses of the inactivated vaccine Coronavac or two doses of BNT162b2.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 122 is below the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Pontificia Universidad Catolica de Chile is the lead sponsor of 215 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Cancer patients receiving their care at the Red de Salud UC Christus in Santiago Chile will be invited
Exclusion Criteria:
Cancer patients on active cytotoxic treatment who received three doses of BNT162b2.
Biological: Three doses of BNT162b2 (observational)
Cancer patients on active cytotoxic treatment who received two doses of Coronavac and one dose of BNT162b2.
Biological: Two doses of Coronavac and one dose BNT162b2 (observational)
BNT162b2 (COVID 19 mRNA vaccine)
BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)
Proportion of positive neutralizing antibodies 8 to 12 weeks after third dose BNT162b2 (booster vaccine).
Time frame: 8 to12 weeks after third dose BNT162b2.
Neutralizing geometric mean titers 8 to 12 weeks after third dose BNT162b2 (booster vaccine)
Time frame: 8 to12 weeks after third dose BNT162b2.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pontificia Universidad Catolica de Chile